Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Gains from Investment Securities (2011 - 2025)

Utah Medical Products' quarterly Gains from Investment Securities came in at $121000.0 in Q4 2025, up 23.47% year-on-year from $98000.0 in Q4 2024, and up 23.47% quarter-over-quarter from $98000.0 in Q4 2024.

Utah Medical Products has reported Gains from Investment Securities for 15 years, with the latest figure at $121000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 23.47% year-over-year to $121000.0; the trailing twelve-month figure through Dec 2025 stood at $121000.0 (up 23.47% YoY), and the FY2025 full-year result was $121000.0, up 23.47% from the prior year.
  • Gains from Investment Securities for Q4 2025 stood at $121000.0, up from $98000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $121000.0 in Q4 2025, with the low at $52000.0 in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $84400.0, with a median of $84000.0 recorded in 2023.
  • Year-over-year, Gains from Investment Securities decreased 24.64% in 2021 and gained 28.85% in 2022.
  • Tracing UTMD's Gains from Investment Securities over 5 years: stood at $52000.0 in 2021, then advanced by 28.85% to $67000.0 in 2022, then rose by 25.37% to $84000.0 in 2023, then advanced by 16.67% to $98000.0 in 2024, then gained by 23.47% to $121000.0 in 2025.
  • The last three Gains from Investment Securities figures came in at $121000.0 (Q4 2025), $98000.0 (Q4 2024), and $84000.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Utah Medical Products 204.80 Mn 117.39 Mn 5.28 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 121,000.00
Dec 31, 2025 121,000.00
Dec 31, 2024 98,000.00
Dec 31, 2024 98,000.00
Dec 31, 2023 84,000.00
Dec 31, 2023 84,000.00
Dec 31, 2022 67,000.00
Dec 31, 2022 67,000.00
Dec 31, 2021 52,000.00
Dec 31, 2021 52,000.00
Dec 31, 2020 69,000.00
Dec 31, 2020 69,000.00
Dec 31, 2019 52,000.00
Dec 31, 2019 52,000.00
Dec 31, 2018 61,000.00
Dec 31, 2018 61,000.00
Dec 31, 2017 54,000.00
Dec 31, 2017 54,000.00
Dec 31, 2016 75,000.00
Dec 31, 2016 75,000.00
Dec 31, 2015 62,000.00
Dec 31, 2015 62,000.00
Dec 31, 2014 91,000.00
Dec 31, 2014 91,000.00
Dec 31, 2013 91,000.00
Dec 31, 2013 91,000.00
Dec 31, 2012 150,000.00
Dec 31, 2012 150,000.00
Dec 31, 2011 238,306.00
Dec 31, 2011 238,306.00